Chengdu Kanghong Pharmaceutical Group Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Founded in 1996, Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Kanghong Pharmaceutical" or "the Group") is a pharmaceutical group dedicated to the research, development, production, sales and after-sales service of biological products, traditional Chinese patent medicines and simple preparations, chemical drugs and medical devices. It has advanced research and development centers and standard industrial production bases, and its marketing network spreads all over the country. On June 26, 2015, Kanghong Pharmaceutical was officially listed on the Shenzhen Stock Exchange (stock code: 002773). Kanghong Pharmaceutical promotes the continuous innovation of quality management with the mechanism of "continuous improvement", which runs through the whole life cycle of products, to maintain the compliance, progressiveness, scientificity and effectiveness of quality management, and to promote Kanghong to become a quality and benefit oriented enterprise. Kanghong Pharmaceutical carries out comprehensive quality control throughout the entire process of product research and development, production, and circulation, strictly adhering to the requirements of "data integrity", and always adhering to the quality philosophy of "quality comes from design, quality comes from control, and quality comes from innovation". Implement quality management standards for drug research and development during the research and development process, implement the concept of cGMP in the production process, and follow GSP standards in the circulation process. Kanghong Pharmaceutical's quality system, based on meeting Chinese requirements, vigorously promotes the internationalization of its quality management system, such as FDA, EU, ICH, and ISO9001 quality management concepts. Kanghong's quality operation principle is "the quality operation department is an active partner of the company, promoting a risk based and scientific quality culture to ensure that quality operation can maximize support and achieve the company's business goals and long-term planning". For more than 20 years, Kanghong Pharmaceutical has adhered to the corporate philosophy of "benefiting the world and benefiting all living beings", firmly adhering to the cultural concept of "gratitude in the heart, return in action", bravely taking on corporate social responsibility, and continuously improving social contribution rate. The group has long been committed to continuous efforts in targeted poverty alleviation, donation for education, earthquake relief, charity clinics, patient assistance, and public cultural dissemination. In 2018, the group launched the release of the "Social Responsibility Report". In 2019, the group was awarded the title of Advanced Private Enterprise in the National "Ten Thousand Enterprises Helping Ten Thousand Villages" Precision Poverty Alleviation Action by the All China Federation of Industry and Commerce and the State Council Poverty Alleviation Office. In addition, the group has established a series of brand public welfare projects with the "Langshi Jiemu Guangming" public welfare fund as the core, continuously deepening the group's public welfare activities. The rapid development of Kanghong Pharmaceutical has received attention and guidance from governments at all levels and widespread attention from various sectors of society, and has repeatedly won various honors. Since 2008, as one of the first seven pharmaceutical enterprises in China to be rated as "AAA level credit enterprises" in credit evaluation, the group has been awarded this level multiple times; In 2009, the trademark was recognized as a "well-known trademark in China" by the State Administration for Industry and Commerce; In 2010, the Group was listed by the China National Intellectual Property Administration as a "national enterprise and public institution intellectual property pilot unit"; In 2011, it was awarded the title of "Top 10 Innovative Enterprise Brands in the Chinese Chemical and Pharmaceutical Industry" by the China Chemical Industry Association; In 2012, it was listed as the fifth batch of "innovative pilot enterprises" by the Ministry of Science and Technology of the People's Republic of China, the State owned Assets Supervision and Administration Commission of the State Council, and the All China Federation of Trade Unions; In March 2016, Conbercept Eye Injection was rated as the "most clinically valuable innovative drug"; In April, Mr. Ke Zunhong, the Chairman of the Group, was awarded the National Medical and Pharmaceutical Award for Science and Technology Tasks by the Ministry of Science and Technology - the "2015 China Pharmaceutical Development Award for Outstanding Achievements in Innovative Drugs". In 2018, the group was awarded the title of "National Technological Innovation Demonstration Enterprise" by the Ministry of Industry and Information Technology of China. |
| Headquarter | Chengdu |
| Establish Date | 10/3/1996 |
| Listed Code | 002773.SZ |
| Listed Date | 6/26/2015 |
| Chairman | Ke Zunhong. |
| CEO | Ke Xiao. |
| Website | www.cnkh.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
